Seminars in Oncology

Papers
(The TQCC of Seminars in Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
KRAS mutation in pancreatic cancer109
Axillary surgery in breast cancer: An updated historical perspective60
Systemic therapy for metastatic HER2-positive breast cancer50
Are sex discordant outcomes in COVID-19 related to sex hormones?41
Breast cancer survivorship36
Implications of reactive oxygen species on cancer formation and its treatment36
Cancer diagnosis in Brazil in the COVID-19 era31
Chemotherapy-induced peripheral neuropathy and rehabilitation: A review30
Novel radiation therapy approaches for breast cancer treatment28
The evolving management of metastatic triple negative breast cancer28
Homologous recombination repair deficiency as a therapeutic target in sarcoma26
Management of hormone receptor-positive, HER2-negative early breast cancer25
Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center24
Early stage triple negative breast cancer: Management and future directions24
Management of ER positive metastatic breast cancer22
Going viral: A brief history of Chilblain-like skin lesions (“COVID toes”) amidst the COVID-19 pandemic21
COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature16
Harnessing natural killer cells for the treatment of multiple myeloma12
Radiation recall dermatitis: A review of the literature12
Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China12
Combination therapy in metastatic renal cell carcinoma: Back to the future?11
Current controversies in breast cancer screening11
Irreversible electroporation of locally advanced pancreatic cancer11
Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma tre11
The heterogeneity of Epithelioid Hemangioendothelioma (EHE): A case series and review of the literature with emphasis on treatment options11
Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management10
Radiotherapy for locally advanced pancreatic ductal adenocarcinoma10
A review of immune checkpoint blockade in breast cancer10
Novel targeted therapies for advanced non-small lung cancer10
Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview10
Liquid Biopsy, the hype vs. hope in molecular and clinical oncology10
Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-1910
Future directions in drug development in pancreatic cancer9
Neoadjuvant chemotherapy for gastric cancer. Has the time to decelerate the enthusiasm passed us by?8
Pancreatic ductal adenocarcinoma in the era of precision medicine8
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer8
Management problems in patients with pancreatic cancer from a surgeon's perspective8
COVID-19 and the cancer care workforce: From doctors to ancillary staff8
Depression in women with a diagnosis of breast cancer. Prevalence of symptoms of depression in Peruvian women with early breast cancer and related sociodemographic factors7
Pathogenic signaling in multiple myeloma6
Epidemiology and genetics of early onset colorectal cancer—African overview with a focus on Ethiopia6
Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies6
Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain6
The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma6
The psychosocial and emotional experiences of cancer patients during the COVID-19 pandemic: A systematic review6
Advances and current concepts in reconstructive surgery for breast cancer6
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics6
Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias6
Landmark trials in the medical oncology management of early stage breast cancer6
Risk-based Approaches for Optimizing Treatment in HER2-Positive Early Stage Breast Cancer5
Impact of CT screening in lung cancer: Scientific evidence and literature review5
Non-pharmacologic interventions for improving cancer-related fatigue (CRF): A systematic review of systematic reviews and pooled meta-analysis5
The Impact of HIV on Non-AIDS defining gastrointestinal malignancies: A review5
Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far5
Barriers and facilitators to lung cancer screening and follow-up5
Daratumumab: A review of current indications and future directions5
Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriers5
0.02528190612793